NCT07902219Not yet recruitingPhase 2
Qurse Revand for MASLD: A Randomized Controlled Safety and Efficacy Trial
Evaluation of Safety and Efficacy of Qurse Revand in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Double-Blind Placebo-Controlled Clinical Trial
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety, efficacy of the Unani compound formulation Qurse Revand compared to a placebo in adult participants with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 128 (estimated)
- First submitted
- 8 Oct 2026
- Start date
- 1 May 2027
- Primary completion date
- 1 May 2029
- Lead sponsor
- National Institute of Unani Medicine, Bengaluru
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT07902219
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 128
- From 1 May 2027 to the primary completion date, 1 May 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants on medications causing steatosis (Amiodarone, Valproic Acid, Methotrexate, Tamoxifen, Glucocorticoids)
Other illness
- Known History of Hepatitis, Liver Cancer, systemic disorders like Malignancies, cardiovascular diseases.
Other
- Pregnant And Lactating Mother
- Fatty Liver Grade Ⅲ (by USG)
Who the study is looking for
- Diagnosed Cases of Fatty Liver (Grade Ⅰ \&Ⅱ) by USG.
- Participants with Presence of at least 1or more cardiometabolic risk factor
- Excess adiposity (BMI of ≥25 kg/m², Waist circumference of ≥94 cm in men and ≥80 cm in women)
- Disorders of glucose metabolism (Prediabetes- HbA1c (5.7% to 6.4 %), FPG- 100 to 125 mg/dL, Type 2 diabetes mellitus- HbA1c of ≥6.5%; FPG of ≥126 mg/dL)
- Hypertriglyceridemia (Plasma triglycerides ≥150 mg/dL)
- High-density lipoprotein (HDL) cholesterol: \<40 mg/dL in men or ≤50 mg/dL in women
- Arterial hypertension: Resting blood pressure of 130/85 mm Hg or greater or ongoing antihypertensive treatment
- Participants with minimal or no alcohol intake (i.e. \<20 g/day for females and \<30 g/day for males).
- Participants of any gender, aged between 20-60yrs.
Age in the registry: 20 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Institute of Unani Medicine Bangalore Coordinator of this site? Confirm its status | Bangalore | India | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.